Biologic and clinical characteristics at diagnosis and clinical outcome according to BCL2-938C>A genotypes
| . | BCL2-938 AA genotype . | BCL2-938 CC genotype . | BCL2-938 AC genotype . | P* . |
|---|---|---|---|---|
| Biologic variables | ||||
| CD38 over 30% | 12/47 (25.5) | 12/39 (30.8) | 35/94 (37.2) | .361 |
| IGHV homology over 98% | 14/44 (31.8) | 9/39 (23.1) | 41/94 (43.6) | .070 |
| IGHV3-21 | 0 | 2/38 (5.3) | 5/94 (5.3) | .297 |
| Normal FISH | 7/43 (16.3) | 10/38 (26.3) | 20/90 (22.2) | .539 |
| del 13q | 26/43 (60.5) | 22/38 (57.9) | 47/90 (52.2) | .635 |
| +12 | 11/43 (25.6) | 9/38 (23.7) | 24/90 (26.7) | .939 |
| del 11q | 2//43 (4.7) | 2/36 (5.3) | 8/90 (8.9) | .597 |
| del 17p | 5/43 (11.6) | 2/38 (5.3) | 11/90 (12.2) | .485 |
| Clinical variables‡ | ||||
| Age, y | 68 (60-75) | 70 (63-77) | 69 (61-76) | .790 |
| Male | 28/47 (59.6) | 18/39 (46.2) | 54/95 (56.8%) | .415 |
| Rai | .130 | |||
| 0 to II | 39/4 (83.0) | 37/39 (94.9) | 78/96 (81.2) | |
| III to IV | 8/47 (17.0) | 2/39 (5.1) | 18/96 (18.8) | |
| Binet | .100 | |||
| A | 35/47 (74.5) | 34/39 (87.2) | 63/96 (65.6) | |
| B | 5/47 (10.6) | 4/39 (10.3) | 15/96 (15.6) | |
| C | 7/47 (14.9) | 1/39 (2.6) | 18/96 (18.8) | |
| Nodal areas over 3 | 5/47 (10.6) | 5/39 (12.8) | 23/95 (24.2) | .090 |
| Lymph node over 3 cm | 5/47 (10.6) | 4/39 (10.3) | 17/95 (17.9) | .363 |
| Splenomegaly | 10/47 (21.3) | 3/39 (7.7) | 20/95 (21.1) | .157 |
| PB lymphocytes, ×109/L | 9.7 (6.1-17.2) | 8.2 (6.1-19.2) | 14.0 (6.6-24.3) | .103 |
| Hb g/L | 13 (123-148) | 135 (126-144) | 137 (120-145) | .761 |
| Platelets, ×109/L | 190 (126-237) | 190 (161-210) | 186 (135-221) | .806 |
| LDT less than 12 mo | 6/38 (15.8) | 4/36 (11.1) | 17/77 (22.1) | .340 |
| BM lymphocytes (%) | 4 (20-60) | 40 (25-60) | 40 (26-70) | .422 |
| Diffuse BM pattern | 11/47 (23.4) | 5/39 (12.8) | 29/94 (30.9) | .090 |
| B2M (mg/L) | 2.2 (1.7-3.4) | 2.3 (1.7-2.9) | 2.5 (2.5-3.6) | .469 |
| LDH (U/L) | 355 (299-433) | 340 (288-407) | 362 (304-445) | .220 |
| ALP (U/L) | 156 (133-209) | 146 (128-177) | 154 (125-171) | .436 |
| Albumin (g/L) | 42 (39-44) | 42 (39-44) | 42 (39-45) | .345 |
| Outcome, % (95% CI) | ||||
| 5-year TFS | 58.1 (41.3-74.9) | 50.0 (28.5-71.5) | 46.4 (34.7-58.1) | .228 |
| 5-year OS | 80.1 (65.1-95.1) | 76.1 (58.7-93.5) | 76.8 (65.3-88.3) | .900 |
| . | BCL2-938 AA genotype . | BCL2-938 CC genotype . | BCL2-938 AC genotype . | P* . |
|---|---|---|---|---|
| Biologic variables | ||||
| CD38 over 30% | 12/47 (25.5) | 12/39 (30.8) | 35/94 (37.2) | .361 |
| IGHV homology over 98% | 14/44 (31.8) | 9/39 (23.1) | 41/94 (43.6) | .070 |
| IGHV3-21 | 0 | 2/38 (5.3) | 5/94 (5.3) | .297 |
| Normal FISH | 7/43 (16.3) | 10/38 (26.3) | 20/90 (22.2) | .539 |
| del 13q | 26/43 (60.5) | 22/38 (57.9) | 47/90 (52.2) | .635 |
| +12 | 11/43 (25.6) | 9/38 (23.7) | 24/90 (26.7) | .939 |
| del 11q | 2//43 (4.7) | 2/36 (5.3) | 8/90 (8.9) | .597 |
| del 17p | 5/43 (11.6) | 2/38 (5.3) | 11/90 (12.2) | .485 |
| Clinical variables‡ | ||||
| Age, y | 68 (60-75) | 70 (63-77) | 69 (61-76) | .790 |
| Male | 28/47 (59.6) | 18/39 (46.2) | 54/95 (56.8%) | .415 |
| Rai | .130 | |||
| 0 to II | 39/4 (83.0) | 37/39 (94.9) | 78/96 (81.2) | |
| III to IV | 8/47 (17.0) | 2/39 (5.1) | 18/96 (18.8) | |
| Binet | .100 | |||
| A | 35/47 (74.5) | 34/39 (87.2) | 63/96 (65.6) | |
| B | 5/47 (10.6) | 4/39 (10.3) | 15/96 (15.6) | |
| C | 7/47 (14.9) | 1/39 (2.6) | 18/96 (18.8) | |
| Nodal areas over 3 | 5/47 (10.6) | 5/39 (12.8) | 23/95 (24.2) | .090 |
| Lymph node over 3 cm | 5/47 (10.6) | 4/39 (10.3) | 17/95 (17.9) | .363 |
| Splenomegaly | 10/47 (21.3) | 3/39 (7.7) | 20/95 (21.1) | .157 |
| PB lymphocytes, ×109/L | 9.7 (6.1-17.2) | 8.2 (6.1-19.2) | 14.0 (6.6-24.3) | .103 |
| Hb g/L | 13 (123-148) | 135 (126-144) | 137 (120-145) | .761 |
| Platelets, ×109/L | 190 (126-237) | 190 (161-210) | 186 (135-221) | .806 |
| LDT less than 12 mo | 6/38 (15.8) | 4/36 (11.1) | 17/77 (22.1) | .340 |
| BM lymphocytes (%) | 4 (20-60) | 40 (25-60) | 40 (26-70) | .422 |
| Diffuse BM pattern | 11/47 (23.4) | 5/39 (12.8) | 29/94 (30.9) | .090 |
| B2M (mg/L) | 2.2 (1.7-3.4) | 2.3 (1.7-2.9) | 2.5 (2.5-3.6) | .469 |
| LDH (U/L) | 355 (299-433) | 340 (288-407) | 362 (304-445) | .220 |
| ALP (U/L) | 156 (133-209) | 146 (128-177) | 154 (125-171) | .436 |
| Albumin (g/L) | 42 (39-44) | 42 (39-44) | 42 (39-45) | .345 |
| Outcome, % (95% CI) | ||||
| 5-year TFS | 58.1 (41.3-74.9) | 50.0 (28.5-71.5) | 46.4 (34.7-58.1) | .228 |
| 5-year OS | 80.1 (65.1-95.1) | 76.1 (58.7-93.5) | 76.8 (65.3-88.3) | .900 |
Data are number/total number (%) or median (25th-75th percentile) unless otherwise specified.
IGHV indicates immunoglobulin heavy chain variable genes; FISH, fluorescent in situ hybridization; PB, peripheral blood; Hb, hemoglobin; BM, bone marrow; B2M, beta-2-microglobulin; ALP, alkaline phosphatase; TFS, treatment free survival (measured from the date of diagnosis to date of first treatment, last follow-up or death); and OS, overall survival (measured from date of diagnosis to date of death or last follow-up).
Continuous variables were compared by Kruskal-Wallis test; categorical variables were compared by χ2 test; TFS was compared by log-rank test; P value cutoff: .05.
If not otherwise specified, continuous variables are indicated as median and quartiles